OPN-019 / Paratek Pharmaceuticals - LARVOL DELTA

Paratek Pharmaceuticals Acquires Optinose in $330 Million Deal to Expand Drug Portfolio (GeneOnline) - "Paratek Pharmaceuticals has finalized the acquisition of Optinose in a deal valued at approximately $330 million. The transaction expands Paratek’s commercial portfolio, adding new products to its lineup and strengthening its position in the pharmaceutical market. The acquisition marks a significant step for Paratek as it integrates Optinose’s assets into its operations. Optinose is known for its innovative approaches to drug delivery, particularly in treating chronic nasal conditions. By acquiring the company, Paratek gains access to these technologies and products, potentially enhancing its ability to address unmet medical needs. The financial details of the agreement place the value of the acquisition at nearly $330 million, underscoring the strategic importance of this move for both companies involved."

M&A • CNS Disorders • Migraine • Pain

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19 (clinicaltrials.gov) - P1 | N=8 | Terminated | Sponsor: Optinose US Inc. | N=30 ➔ 8 | Recruiting ➔ Terminated; Sponsor Decision

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19 (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Optinose US Inc.

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease

Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights (GlobeNewswire) - "In April 2021, the Company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. This pilot study being conducted in Mexico will evaluate both the magnitude and duration of viral load reduction after a single dose of OPN-019. The Company expects top-line results from this study in second quarter 2021."

Clinical data • New trial • Trial status • Infectious Disease • Novel Coronavirus Disease

Optinose Announces Anti-COVID-19 Product Candidate (GlobeNewswire) - "Optinose...today announced initiation of development of a new product candidate, OPN-019. OPN-019 will combine the Company’s proprietary nasal Exhalation Delivery System (EDS)....The Company expects to be able to rapidly progress to a meeting with FDA to discuss an IND and then onward to clinical trials. The Company is focused on supporting the initial stages of development within its current operating expense plan and intends to seek grants, partnerships..."

FDA event • New molecule • Infectious Disease • Novel Coronavirus Disease